
The Transcreener® ADP2 FP Assay from BellBrook Labs is an extremely sensitivite ADP Assay with a more sensitive antibody against ADP yielding an excellent signal at less than or equal to 10% ATP consumption for a broad range of initial ATP concentrations (0.1-1,000 μM). The result is the ability to screen low ATP Km enzymes, and to use initial velocity enzyme kinetics at or below ATP Km concentrations, which leads to accurate inhibitor potencies and the ability to use less enzyme and substrate. Ratiometric, red-shifted fluorescence polarization output minimizes signal variability and reduces compound interference.
The Transcreener® ADP2 Assay is a fluorescence polarization immunoassay based on the detection of ADP by an antibody. This assay platform provides the possibility to universally interrogate all enzymes that catalyze group transfer reactions with ATP. In step one of the assay, enzymes catalyze the transfer of phosphate from ATP to a protein, peptide, lipid or small molecule resulting in the accumulation of ADP.
BMG LABTECH has also published Transcreener® ADP FP Application Notes (AN) with BellBrook Labs:
The following BMG LABTECH microplate readers are Transcreener® ADP2 FP certified from BellBrook Labs:
![]() |
![]() |
![]() |
For more information about the Transcreener® ADP2 FP Assay and other Transcreener® technologies visit:
http://www.bellbrooklabs.com